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Objective To evaluate the responsiveness of the ICSmale symptoms. Patients received a range of treatments:
32% TURP, 29% drug therapies, 20% watchful wait-questionnaire to the outcome of treatments for lower
urinary tract symptoms (LUTS). ing, 9% minimally invasive therapies and 10% ‘others’
(including open prostatectomy). For patients whoPatients and methods Consecutive men aged >45 years
attending 23 urology centres in 12 countries, with underwent TURP, most LUTS, including voiding and
filling symptoms, were highly statistically significantlysymptoms suggestive of bladder outlet obstruction
secondary to benign prostatic hyperplasia (BPH), were better at follow-up than at baseline (P<0.0001). For
drug, minimally invasive and ‘other’ treatments, fewerrecruited to Phase I of the International Continence
Society (ICS)-‘BPH’ study. In Phase II of the ICS-‘BPH’ LUTS were highly statistically significantly better. For
those undergoing watchful waiting, no symptoms werestudy, 355 men in 15 centres in nine countries were
followed up, having proceeded to treatment according significantly diCerent between baseline and follow-up.
Conclusion The ICSmale questionnaire, in addition toto clinical practice. All men completed the ICS-‘BPH’
study questionnaire at baseline and follow-up, including being psychometrically valid and reliable, is responsive
to change in outcome.the ICSmale which concerns LUTS and related problems.
Results Patients included in Phase II were similar to Keywords Questionnaire, lower urinary tract symptoms,
quality of life, benign prostatic hyperplasiathose in Phase I according to age and levels of baseline
i.e. frequency, incomplete emptying, intermittency,Introduction
urgency, weak stream, hesitancy and nocturia [2], while
it has been shown that men with LUTS experience aIncreasingly, questionnaires are being used to assess
symptoms and the impact on quality of life of men with much wider range of symptoms, some of which are
considerably more troublesome than those included inLUTS related to benign prostatic disease, e.g. the AUA
symptom score [1], IPSS [2], DAN-PSS-1 [3], Maine the IPSS [3,5,10]. Recently, data indicating that the
DAN-PSS may be more sensitive to outcome have beenMedical Assessment Program [4], ICSmale questionnaire
[5], Bolognese Questionnaire [6], BPH-HRQOL measure published [11].
The ICSmale questionnaire is a wide-ranging question-[7], BPH Impact Index [8] and ICSQoL questionnaire [9].
The most widely used measure, the IPSS, is now used naire including 20 symptom questions in total, most of
which also have a sub-question attached concerning thecommonly in randomized trials and other evaluative
studies to assess outcome, particularly symptom degree of problem caused. Thus far, the ICSmale question-
naire has been shown to be psychometrically valid andimprovement after intervention. However, there are con-
cerns that the IPSS only encompasses some aspects of reliable at baseline [5]. However, it is important that
questionnaires used to assess outcome are evaluatedoutcome. In particular, it contains only seven symptoms,
to ensure that they are appropriately responsive to
changes over time or after interventions. The ICSmaleAccepted for publication 29 September 1998
243© 1999 BJU International
244 J .L. DONOVAN et al.
questionnaire was developed during Phase I of the Statistical methods
ICS-‘BPH’ study, a large international study whose main
Frequency distributions were obtained for symptoms
aim was to investigate the relationships between reported
and related problems caused; anova and Student-
symptoms and the results of urodynamic studies [12].
Newman-Keuls tests were used for comparisons
Phase II of the study has involved an observational
between treatment groups with respect to age and
follow-up of patients recruited to Phase I in centres
length of follow-up [15]. An extension of Fisher’s exact
willing to collaborate with this activity. This article
test was also used for comparing proportions. The
reports on the evaluation of the responsiveness of the
Wilcoxon signed-ranks test for paired data was used to
ICSmale questionnaire to outcome after treatment among
determine whether baseline and follow-up
patients in Phase II of the ICS-‘BPH’ study.
questionnaire items diCered significantly within each
treatment group. To adjust for multiple significance
Patients and methods testing, a Bonferroni correction which maintains a 5%
overall significance level would indicate that test-wise
In all, 1271 consecutive men aged >45 years, and
P values should only be considered significant if they
attending 23 urology departments in 12 countries, with
are <0.0025 for these comparisons [15].
symptoms suggestive of BOO secondary to BPO were
recruited to Phase I of the ICS-‘BPH’ study [13]. Men
Resultswere excluded if they had significant urological disease
(e.g. prostate cancer), neurological disease, had under-
ICSmale questionnaire data were available for 355
gone previous prostatic surgery, or were taking medi-
patients followed after their initial recruitment from the
cation active on the lower urinary tract. Each patient
following countries; Table 1 shows the numbers and
underwent a physical examination, uroflowmetry and
proportions of patients followed. As only a proportion of
pressure-flow studies, and completed the ICS-‘BPH’ study
patients was followed, it was important to examine
questionnaire which includes the ICSmale questionnaire
whether they were diCerent from the baseline group
[10]. Results concerning the psychometric validity and
according to age and symptom levels. The proportions
reliability of the ICSmale questionnaire at baseline have
in each of the 10-year age bands were very similar for
been reported elsewhere [5].
the follow-up group compared with the original
Fifteen centres in nine countries agreed to participate
ICS-‘BPH’ study baseline sample: 24% in those
in Phase II of the study. Patients proceeded to treatment
<60 years at follow-up, compared with 21% at baseline,
according to normal clinical practice and clinicians were
41% compared with 43% for the 60–69 years group,
asked to follow patients up #12 months after the
and 35% compared with 36% for those >70 years. The
baseline evaluation; 422 patients in total were followed-
followed patients were also very similar to the full
up in Phase II of the ICS-‘BPH’ study, 355 of whom
baseline sample in terms of their levels of ‘any mention
completed the ICSmale questionnaire in full (84%).
of a symptom’; eight symptoms were diCerent by either
Evaluating the responsiveness of the ICSmale questionnaire
Table 1 Patients included in Phase II of the ICS-‘BPH’ study,
by countryThere has been considerable controversy about the most
appropriate methods of measuring change using ques-
No. of patients (%) attionnaires. There are three main aspects to the measure-
ment of change; diCerentiating between those who Follow-up
change a great deal and those who change little, the Country Baseline ICSmale Died
identification of factors which are associated with a good
outcome, and inferring treatment eCects from group Netherlands 391 144 (37) 2
Italy 58 48 (83)diCerences, commonly in clinical trials [14]. Where a
Denmark 121 36 (30)questionnaire results in a simple score, treatment eCects
Japan 66 31 (47) 1can be assessed by examining diCerences before and after
Australia 47 21 (46) 1treatment between the intervention and control group,
Portugal 49 18 (37)
using unpaired t-tests, analysis of covariance or repeated- Germany 75 14 (19)
measures anova [14]. However, the ICSmale question- UK* 66 33 (50)
naire does not produce a simple score and so responsive- Israel 10 10 (100)
ness of each question was examined by comparing
baseline and follow-up symptom levels for each of the *Includes 13 patients too late to be included in the original
ICS-‘BPH’ study baseline dataset.major treatment groups.
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Table 2 Type of treatment by country, by age in 10-year age For patients who underwent TURP, most LUTS (15 in
bands and the mean follow-up all) were highly statistically significantly better at follow-
up than baseline (P<0.0001), i.e. frequency, nocturia,
Type of treatment, n (%)
urgency, urge incontinence, bladder pain, hesitancy,
straining to start, straining to continue, reduced stream,Country TURP MIT WW Drugs Other
intermittency, dysuria, incomplete emptying, terminal
dribble, post-void dribble, and repeated urination.Netherlands 16 (11) 20 (14) 52 (36) 52 (36) 4 (3)
Italy 36 (75) 0 1 (2) 7 (15) 4 (8) Figure 1 shows the proportions of men with any mention
Denmark 21 (58) 5 (14) 5 (14) 2 (6) 3 (8) of a symptom before and after each treatment. For
Japan 11 (35) 6 (19) 5 (16) 7 (23) 2 (7) patients who received ‘other’ treatments, seven symp-
Australia 11 1 2 1 6 toms were highly statistically significantly better at
Portugal 3 0 4 7 4
follow-up than baseline (P<0.0001), i.e. nocturia, hesi-Germany 0 0 0 14 0
tancy, strain to start, strain to continue, reduced stream,UK 15 (45) 1 (3) 2 (6) 4 (12) 11 (33)
intermittency, terminal dribble; and five more, i.e.Israel 2 0 1 7 0
urgency, urge incontinence, dysuria, repeated urination
Age distribution, years and frequency, were significantly better (P<0.0025;
<60 22 (20) 7 (23) 15 (24) 24 (26) 6 (27) Fig. 1). For patients who received minimally invasive
60–69 39 (36) 18 (58) 29 (46) 36 (41) 7 (32) treatments, there were fewer LUTS (four) that were
>70 47 (44) 6 (19) 19 (30) 29 (33) 9 (41)
highly statistically significantly better at follow-up than
at baseline (P<0.0001); nocturia, hesitancy, reducedMean follow-up, 22 15 10 11 22
stream and intermittency; with urgency and frequencymonths
significantly better (P<0.0025; Fig. 1). For those receiv-
ing drug treatment, five LUTS reached the highest levelMIT, Minimally invasive treatment.
of statistical significance (P<0.0001), i.e. nocturia,
urgency, hesitancy, reduced stream and incomplete emp-0 or 1%, and nine by 2–4%. Only incomplete emptying
varied by more than this, i.e. 81% in the baseline sample tying, with five more (bladder pain, strain to continue,
intermittency, post-void dribble and repeated urination)compared with 75% in the follow-up group.
Patients were followed for a mean of 16 months after significantly better (P<0.0025). For those undergoing
watchful waiting, no LUTS were significantly diCerentbaseline (range 2–44). Of the 355 men followed, 115
(32%) underwent TURP, 101 (29%) drug treatment, 72 between baseline and follow-up (Fig. 1).
All symptoms reaching statistical significance showed(20%) watchful waiting, 33 (9%) a minimally invasive
therapy (including 11 microwave, nine laser, 13 transur- an improvement between baseline and follow-up, with
the proportion of men improving being considerablyethral incision) and 34 (10%) some other procedure,
including 10 an open prostatectomy. Follow-up times higher for those undergoing TURP than other treat-
ments. Table 3 shows the percentage change in ‘anywere statistically significantly diCerent between the treat-
ment groups (Table 2; P<0.001). A Student-Newman- mention of a symptom’ between baseline and follow-up.
The diCerent treatments had clearly diCerent impacts onKeuls test, maintaining a 5% experiment-wise signifi-
cance level, indicated that the diCerences were statisti- symptoms, with the surgical treatments (TURP, ‘other’
and minimally invasive therapies) having the greatestcally significant only between surgical (particularly
TURP and other treatments) and more conservative impact, and drugs and watchful waiting the least.
The picture was similar for the problems caused; prob-treatments (drug and minimally invasive therapies, and
watchful waiting). lems relating to 10 LUTS (nocturia, urgency, hesitancy,
strain to start, strain to continue, reduced stream, inter-Table 2 also shows the diCerences in treatments by
countries in Phase II of the study. The treatments mittency, incomplete emptying, terminal dribble and fre-
quency) were statistically significantly better at follow-upreceived were statistically significantly diCerent between
countries, with patients in Italy, Denmark, Australia, than baseline for those undergoing TURP (P<0.0025;
Fig. 1). For ‘other treatments’, four LUTS were statisticallyJapan and the UK tending to undergo surgical treat-
ments, and patients from the Netherlands, Portugal, significantly better (frequency, nocturia, urgency and
terminal dribble, P<0.0025). With minimally invasiveIsrael and Germany having more conservative treat-
ments (an extension of the Fisher’s exact test, therapies, problems related only to intermittency were
statistically significantly better (P<0.0025). With drugs,P<0.0001). Table 2 also shows the age distributions
within treatment groups; although older men were more only problems associated with frequency and nocturia
reached this level of significance, and again the watchfullikely to undergo TURP, diCerences between groups were
not statistically significant (anova, P=0.14). waiting group remained stable (Table 3).
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Fig. 1. The proportion of patients reporting ‘any mention of symptom’ for symptoms and problems before (green) and after (red) (a) TURP,
(b) ‘other’ treatments, (c) minimally invasive therapies, (d) drugs and (e) watchful waiting.
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Table 3 The change in symptoms (%) from before to after and ‘other’ treatments), but not after drugs. Straining to
each treatment continue and repeated urination were significantly
improved after drugs and ‘other’ treatments. Urge incon-
Symptom TURP MIT WW Drugs Other
tinence, straining to start, dysuria and terminal dribble
were significantly improved after ‘other’ treatments andNocturia −48 −28 16 14 −41
TURP. Similarly, bladder pain, incomplete emptying andUrgency −27 −19 0 −9 −23
post-void dribble were significantly improved after drugsUrge incontinence −29 9 1 −7 −32
Bladder pain −23 −3 −1 14 −31 and TURP. These patterns suggest that treatments could
Stress incontinence 6 9 −5 1 −18 be targeted towards patients with particular symptom
Misc incontinence −4 −4 6 2 −9 profiles, although these findings will need to be confirmed
Hesitancy −44 −47 4 −10 −40 by further research.
Strain to start −35 −43 −28 −2 −63
The picture was similar for the degree of problemStrain to continue −42 −28 −1 −6 −59
caused by symptoms as for the symptoms themselves,Reduced stream −37 −44 −4 −4 −33
with TURP having the greatest impact, and drugs,Intermittency −34 −10 0 −3 −35
Dysuria −18 −19 0 −11 −39 minimally invasive and ‘other’ treatments having smaller
Incomplete −24 −28 3 −3 −27 eCects, with the watchful-waiting group remaining stable.
emptying Although these results are very significant statistically
Terminal dribbling −19 −16 2 1 −18 and likely to be robust, they are based on observational
Post-void dribble −20 −28 −10 −5 −32
data, and so it is important to consider the existenceNocturnal incontin. −2 −4 −3 −4 −17
and strength of biases that might be present. For example,Repeated urination −37 −34 −6 −19 −43
it is clear that there are similarities as well as diCerencesAcute retention −11 0 5 −1 −6
Frequency −36 −37 0 −7 −38 between the treatment groups in terms of age and
symptom levels. There were no statistically significant
MIT, Minimally invasive treatment. diCerences in age among the treatment groups. Symptom
levels were similar for those undergoing TURP or mini-
mally invasive therapies, and were also similar for thoseDiscussion
receiving drug therapies and watchful waiting. However,
as would be expected, men who underwent surgical,These results suggest that the ICSmale questionnaire is
sensitive to expected changes after interventions. The ‘other’ and minimally invasive treatments had, on the
whole, higher levels of symptoms than those whochanges were most apparent and significant for patients
who underwent TURP, where most LUTS (15 in all) were received more conservative therapies (drugs and watch-
ful waiting).very significantly better at follow-up than at baseline
(P<0.0001). Those who received drug therapies, five It was possible only to follow a proportion of patients
recruited to Phase I of the ICS-‘BPH’ study in Phase II.LUTS were highly significantly better, with five more
significantly so; those receiving ‘other’ therapies also had Centres were requested to follow-up as many patients as
possible, but it is evident from Table 1 that the complete-improvements at follow-up. For minimally invasive therap-
ies, four LUTS were very significantly better at follow-up ness of the follow-up varied between centres. The patients
followed were apparently similar to those who were notthan baseline and two were significantly better. No LUTS
were statistically significantly diCerent between baseline in terms of age distribution and levels of symptoms, but
it remains a possibility that the ICSmale questionnaireand follow-up for those undergoing watchful waiting.
The patterns of symptom improvement are intriguing; may not have been responsive to the outcomes of patients
who were not followed-up.after TURP, the greatest number and widest range of
symptoms were significantly improved, including both Although there are several diCerences between coun-
tries and treatment groups at both baseline [16] andfilling and voiding symptoms. There were no symptoms
that were significantly improved by other treatments but follow-up, the strength of the significant improvements
in symptoms between baseline and follow-up suggestsnot by TURP. There was some consistency in the symp-
toms that were significantly improved by all interventions that the ICSmale questionnaire is sensitive to changes
after interventions. However, these findings will need to(i.e. anything other than watchful waiting), with nocturia,
hesitancy, urgency, intermittency and reduced stream be confirmed by truly comparable patient groups in
randomized controlled trials.significantly improved by all active interventions.
However, there were several symptoms which were In conclusion, the results show that, among patients
who were followed, symptom and problem questions inimproved only after TURP and one or two other treat-
ments; e.g. frequency was significantly improved after the ICSmale questionnaire are sensitive to changes that
might be expected after various treatments. Most LUTSany of the surgical treatments (TURP, minimally invasive
© 1999 BJU International 83, 243–248
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Mebust W. Measuring disease-specific health status in men(and their resultant problems caused) improved signifi-
with benign prostatic hyperplasia. Med Care 1995; 33:cantly after TURP, including both storage and voiding
AS145–AS155symptoms. Fewer symptoms exhibited this pattern for
9 Donovan JL, Kay HE, Peters TJ et al. Using ICSQoL tomen receiving ‘other’ treatments, drugs and minimally
measure the impact of lower urinary tract symptoms oninvasive therapies such as laser and microwave treat-
quality of life: evidence from the ICS-‘BPH’ study. Br J Urol
ment. No significant changes were apparent for those
1997; 80: 712–21
who had undergone watchful waiting. This evidence 10 Peters TJ, Donovan JL, Kay HE et al. The International
suggests that the ICSmale questionnaire, in addition to Continence Society ‘Benign Prostatic Hyperplasia’ Study:
being psychometrically valid and reliable [5] is responsive The bothersomeness of urinary symptoms. J Urol 1997;
to changes in outcome. 157: 885–9
11 Hansen BJ, Mortensen S, Mensink HJA et al. Comparison
of the Danish prostate symptom score with the IPSS,
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